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Abstract
Although aspirin has a well-established role in preventing adverse events in patients with known cardiovascular
disease (CVD), its benefit in patients without a history of CVD remains under scrutiny. Current data have provided
insight into the risks of aspirin use, particularly bleeding, compared with its benefits in primary CVD prevention.
Although aspirin is inexpensive and widely available, especially in developing countries, there is lack of evidence
that the benefits outweigh the adverse events with continuous aspirin use in primary CVD prevention. Therefore,
the decision to initiate aspirin therapy should be an individual clinical judgment that weighs the absolute benefit
in reducing the risk of a first cardiovascular event against the absolute risk of major bleeding, and tailored to the
patient’s CVD risk. This risk must be calculated, based on accurate and cost-benefit locally developed risk assessment
tools, the most discriminating threshold be identified. Additionally, patients preferences should be taken into account
when making the decision to initiate aspirin therapy in primary prevention of CVD or not. Physicians should
continuously be trained to calculate their patients CVD risk, and concomitant strategies be emphasized.
Keywords: Aspirin, Cardiovascular disease, Primary prevention
Introduction
Cardiovascular disease (CVD), of which coronary heart
disease (CHD) and stroke are the prevailing compo-
nents, is by far the leading cause of death in most devel-
oped countries and is rapidly becoming the leading
cause of death in the world [1]. Indeed, the World
Health Organization estimates that annual global mor-
tality due to CVD will approach 25 million by 2030, of
which about 80 % will occur in developing countries [2].
These alarming and potentially avoidable trends result
mainly from major increases in cigarette smoking, obesity,
and physical inactivity in both developed and developing
countries [1].
Because of the prominent role of thrombosis in the
pathogenesis of CVD, anti-thrombotic agents have been
tested for the prevention of CVD. The anti-thrombotic
properties of aspirin were first described in 1971 [3], and
the hypothesis that aspirin could efficiently prevent
CVD was subsequently raised and investigated. In fact,
aspirin therapy can reduce the risk of major cardiovascu-
lar events such as heart attack and stroke [4]. Aspirin is
widely available and very inexpensive as well, and its
utilization in the prevention of CVD would be highly
profitable to the global population, in particular those
without prior CVD, and specifically those living in low-
income countries.
Although there is body of evidence that aspirin is
beneficial in secondary CVD prevention [5, 6], findings
from clinical trials and meta-analyses on aspirin benefit
in primary CVD prevention are not homogenous.
When tested for primary prevention in clinical trials of
predominantly low risk individuals, aspirin has been
shown to decrease the rate of CVD events but at a
near-equivalent risk of increased bleeding [6–9], limit-
ing its use only in individuals at elevated risk for a
cardiovascular event, and thereby withholding aspirin
from lower risk patients who represent the majority of
the primary prevention population and in whom a large
proportion of cardiovascular events occur [10]. Conse-
quently, guidelines and other expert opinions differ
substantially in their recommendations for aspirin use
in primary CVD prevention, reflecting the uncertainty
of a precise risk/benefit ratio in this context.
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Limiting aspirin use to only high-risk individuals negates
the opportunity to prevent a significant number of cardio-
vascular events, many of which present as unheralded
myocardial infarction (MI) or sudden cardiac death [11],
especially in developing countries where alternatives to
aspirin could be unaffordable by the large majority of pri-
mary CVD prevention populations [12–14]. The present
review revisits published knowledge on the safety and effi-
cacy of aspirin use in primary prevention of CVD and
presents current practical recommendations.
Review
The theoretical physiological effects of aspirin in
cardiovascular disease prevention
For a cardiovascular event to occur, the fibrous cap of
an atheromatous lesion must rupture. This plaque
rupture exposes highly pro-thrombotic material leading
to thrombosis [15–17]. Therefore, the prevention of
thrombus formation or the prevention of propagation
of thrombus once it exists will consequently prevent
evolution into full vascular occlusion, hence the utility
of anti-thrombotic agents.
Aspirin is a non-selective cyclo-oxygenase (COX) in-
hibitor. It blocks the production of thromboxane in plate-
lets (by acetylation of COX in platelets) thereby inhibiting
their aggregation, but it also blocks the synthesis of pros-
taglandins in the vascular wall that, in health, causes vaso-
relaxation, maintains renal function, and reduces adhesion
of platelets to the vessel wall [3, 18]. Furthermore, aspirin
may be beneficial for atherosclerosis not only because of
its antiplatelet action, but also by showing a direct effect
on the atheroma plaque. Indeed, Redondo et al. have un-
doubtedly demonstrated that aspirin increases the stability
of the atheroma plaque (or significantly inhibits plaque
growth), this mediated by an increase in TGF-β secretion
[19, 20]. These properties of aspirin have consequently
brought to explore the benefits of this drug in CVD pre-
vention. However, the use of aspirin, especially in the long
term, is not without some harmful effects that can even
become fatal.
Adverse events with aspirin
The major drawback to continuous aspirin therapy is
the risk of bleeding. The Antithrombotic Trialists’
Collaboration (ATTC) meta-analysis revealed that as-
pirin use increased the risk of major gastrointestinal
(GI) and other extracranial bleeding by about 50 %
(0.10 %/year vs. 0.07 %/year (risk ratio (RR) 1.54,
95 % confidence interval (CI):1.30–1.82; p <0.0001)
[6]. Aspirin also increases the risk of hemorrhagic
stroke. A meta-analysis of 16 placebo-controlled ran-
domized controlled trials (RCTs), comprising a total
of 55,462 patients, showed that treatment with aspirin was
associated with a relative risk of hemorrhagic stroke of
1.84 (p < 0.001) [21]. Likewise, The ATTC reported a
statistically significant 22 % increased incidence of
hemorrhagic stroke in patients on antiplatelet treatment
[22]. Moreover, De Beradis et al. [23] in comparison with
ATTC estimates, found a 5-time higher incidence of
major bleeding events with an overall incidence rate of
hemorrhagic events of 5.58 (95 % CI: 5.39–5.77) per
1000 person-years for aspirin users and 3.60 (95 % CI:
3.48–3.72) per 1000 person-years for those without as-
pirin use (incidence ratio rate (IRR) 1.55, 95 % CI:
1.48–1.63). In particular, the use of aspirin was associated
with an excess risk of gastrointestinal (IRR 1.55, 95 % CI:
1.46–1.65) and intracranial bleeding (IRR 1.54, 95 % CI:
1.43–1.67) [23]. In the recent Japanese Primary Prevention
Project (JPPP) [24], aspirin significantly increased the risk
of extracranial hemorrhage requiring transfusion or
hospitalization (0.86, 95 % CI: 0.67–1.11 for aspirin vs.
0.51, 95 % CI: 0.37–0.72 for no aspirin; hazard ratio (HR)
1.85, 95 % CI: 1.22–2.81; p = 0.004).
Several other studies have also shown that the risk of
bleeding is increased with aspirin therapy [25–31]. It has
been emphasized that this risk is higher in the primary
prevention than in the secondary prevention population,
but this difference is more than compensated by the
lower baseline risk in primary prevention population
[26]. Likewise, the risk of bleeding is higher in individ-
uals at higher cardiovascular risk over 10 years when
compared with the low-risk population [32]. Further-
more, some other factors likely to dreadfully increase
the risk of bleeding have been identified: increased age,
previous hospitalization for GI problems, helicobacter
pylori infection, male sex, diabetes, hypertension, previ-
ous cardiovascular problems, alcohol use, concurrent
use of nonsteroidal anti-inflammatory drugs (NSAIDs)
or concomitant use of either antiplatelet agents or oral
anticoagulants [6, 23, 33, 34]. These risk factors are
common in the general population and therefore, the in-
dividual patient’s risk of bleeding needs to be taken into
consideration when deciding to put him/her on continu-
ous aspirin therapy, especially in low-income settings
where there may be lack of enough means and compe-
tence to handle such related harmful side effects [14].
Some bleeding risk scores have been developed, espe-
cially in anticoagulated atrial fibrillation (AF) populations,
such as the HEMORR2HAGES score, the HAS-BLED
score, and the less practical ATRIA score. We learn from
Lip G’s review that the HAS-BLED score has been shown
to outperform the other risk scores in predicting clinically
relevant bleeding in multiple ‘real-world’ and trial cohorts
[35]. Additionally, the HAS-BLED score was the only
tested score to have a significant (and good, c-statistic
0.75) predictive value for intracranial haemorrhage [36].
The acronym HAS-BLED represents each of the bleed-
ing risk factors and assigns 1 point for the presence of
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each of the following: hypertension (uncontrolled sys-
tolic blood pressure >160 mmHg), abnormal renal and/
or liver function, previous stroke, bleeding history or
predisposition, labile international normalized ratios,
elderly, and concomitant drugs and/or alcohol excess
[37]. The HAS-BLED score ranges from 0 to 9, with
scores of ≥ 3 indicating high risk of bleeding, for which
caution and regular review of the anticoagulated AF pa-
tient are recommended [35, 38]. In this regard, the ap-
plicability of such a score should be undertaken in
primary prevention of CVD with aspirin, and patients
at high risk of bleeding should not be prescribed aspirin
in primary prevention of CVD.
Moreover, the standard dosage of aspirin (325 mg/day)
is significantly associated with a higher risk of gastro-
intestinal bleeding (including fatal bleeds) than are low-
doses (75–100 mg/day) [39–41], though this risk is
estimated to be twice as high as with no aspirin [42].
Some papers have pointed-out that an increased con-
sumption of proton pump inhibitors (PPIs) might be
associated with a significant reduction in hospitalizations
for gastrointestinal events during continuous aspirin
therapy [23, 43], but the cost-effectiveness of PPIs asso-
ciated with aspirin use, specifically in resource-poor en-
vironments, needs a thorough clarification. Earnshaw et
al. [44] demonstrated that the addition of a PPI to as-
pirin is cost-effective only for men at increased risk for
gastrointestinal bleeding. On the other hand, there have
been some claims that using PPIs might increase the risk
of cardiovascular events in patients treated with anti-
platelet agents [45]. However, it is questionable if the
PPI used (omeprazole) was the cause of this increased
risk of adverse cardiovascular events, or if omeprazole
use was merely a mark of a more severe patient (omep-
razole users tend to be older, more fragile and with more
comorbidities, all factors increasing mortality). Other au-
thors have proposed that aspirin could be substituted by
another anti-thrombotic agent to reduce CVD risk while
eliminating the bleeding risk, but two prospective clinical
trials demonstrated for instance that the combination of
aspirin and esomeprazole was superior to clopidogrel for
the prevention of recurrent ulcer bleeding [46, 47].
Aspirin use is also associated with an increased risk of
dyspepsia, chronic kidney disease and renal dialysis, and
age-related macular degeneration [48]. There is some sug-
gestion that low-dose aspirin (50 mg daily) might not slow
carotid atheroma plaque growth [49]. Consequently, any
effect of aspirin on cardiovascular events needs to be
balanced against the potential for harm. In primary CVD
prevention where the risk of developing atherothrombotic
events is generally low, it is therefore highly relevant to
estimate the individual baseline risk of such events and
carefully balance this against the risk of harmful events re-
lated to therapy.
Assessing the baseline risk in primary prevention of
cardiovascular disease
Commonly-used tools to assess baseline risk are the
Framingham coronary heart disease risk score [32], the
American College of Cardiology/American Heart Associ-
ation (AHA/ACC) Task Force risk equations [50], and the
European Society of Cardiology ESC’s SCORE (Systematic
Coronary Risk Evaluation) [51]. The Framingham risk
score (FRS) utilizes gender, age, total cholesterol, high-
density lipoprotein cholesterol, systolic blood pressure, use
of blood pressure lowering medications, and smoking sta-
tus to predict the 10-year risk of developing a coronary
event (composite of MI and coronary death). Individuals
are categorized as low (<10 %), moderate (10 to 20 %), or
high (>20 %) risk [32]. Moreover, the SCORE system
estimates the 10-year risk of a fatal atherosclerotic event:
individuals are considered at low risk with a SCORE < 1 %,
at moderate risk with a SCORE ≥ 1 % and <5 %, at high
risk with a SCORE ≥ 5 % and <10 %, and at very high risk
with a SCORE ≥ 10 % [51]. The risk of total fatal and non-
fatal events is higher than that of fatal events only. At a
5 % risk of fatal events, the total event risk is approximately
15 %. This 3-fold multiplier is somewhat smaller in the eld-
erly, in whom a first event is more likely to be fatal [51].
Additionally, the Coronary artery calcium (CAC) score
has recently been tested to guide aspirin utilization for pri-
mary prevention of CVD. In fact, one can read from
Miedema et al. [11] that CAC score is a highly specific
marker of the atherosclerotic plaque burden in the coron-
ary arteries, and there is a nearly 10-fold higher risk of
CHD events in patients with substantially elevated CAC.
The same authors report that a CAC score of zero has
been shown to be a powerful predictor of a favorable
prognosis (low risk of CHD, CVD and all-cause mortality),
even in the presence of traditional risk factors [11, 52].
Furthermore, an analysis of 44,052 asymptomatic people
showed that individuals with no cardiovascular risk factors
but elevated CAC had higher mortality rates than indi-
viduals with multiple risk factors but zero CAC [53].
Although CAC may be a promising risk assessment and
reclassification tool, how this test should be used in
routine clinical practice remains unclear, added to its
relatively high cost ($100).
Another tool that has been used is the ankle brachial
index (ABI) which is the ratio of systolic pressure at the
ankle to the arm. It is used in the diagnosis of peripheral
artery disease affecting the legs. A low ABI is associated
with concomitant coronary and cerebrovascular disease
[54], and, in healthy individuals, with an increased risk
of future vascular events, independently of cardiovascu-
lar risk factors [55]. An ABI of 0.90 or less is often used
as the cut point for identifying individuals at high risk of
peripheral atherosclerosis. [55]. In this regard, Fowkes et
al. [28] hypothesized that, because the ABI is a simple,
Nansseu and Noubiap Thrombosis Journal  (2015) 13:38 Page 3 of 10
inexpensive, noninvasive test, it could be used in popula-
tion screening programs (for example in primary care
settings or in the community) to identify a novel sub-
group potentially amenable to preventive treatments.
However, as most of these aforementioned tools
were developed in Caucasian populations, their appli-
cation in other populations or ethnic groups is there-
fore problematic. In this regard, the INTERHEART
risk score was developed based on data from 52 coun-
tries around the world [56]. Yusuf et al. [56] showed
that the INTERHEART risk score, based on nine eas-
ily measureable and potentially modifiable risk factors,
is associated with more than 90 % of the likelihood to
accurately predict an acute MI, these results being
consistent across all geographic regions and ethnic
groups of the world, men and women, and young and
old. More recently, McGorrian et al. [57] modified the
INTERHEART risk score into the INTERHEART
Modifiable Risk Score (IHMRS), of which four risk
score models were derived. Of these, the ‘non-labora-
tory-based’ score [57], which does not include any lab-
based measures of lipid profile, can be used in primary
care settings especially in resource-poor countries
where there is lack of laboratories [14].
Consequently, more observational studies as well as
direct randomized comparisons between all these
commonly-used tools are urgently warranted to define
which is the most reliable and cost-effective one to be
used for primary CVD risk assessment, particularly in
low-income settings [58]. Besides, adoption of continu-
ous aspirin use for primary CVD prevention must be
underpinned by robust scientific evidence.
Published evidence for or against a beneficial effect of
aspirin in primary prevention of cardiovascular disease
In 2009, the ATTC reviewed the benefit-risk profile of
low-dose aspirin for primary CVD prevention in a com-
prehensive meta-analysis of 6 primary prevention trials
that included nearly 95,000 men and women randomly
assigned to aspirin at doses of 75–500 mg per day or pla-
cebo [6]. Aspirin was associated with a 12 % proportional
reduction in serious vascular events compared with no
aspirin (annual event rate 0.51 % for aspirin vs. 0.57 % for
no aspirin, p <0.0001), mainly due to a reduction in first
nonfatal MI (0.18 % vs. 0.23 % per year; p <0.0001), and
the proportional reductions were similar for women and
men [6]. Conversely, aspirin therapy did not seem to have
an effect on stroke occurrence, and it was noticed just a
small protective effect with regard to mortality, given 0 to
6 fewer deaths per 1000 persons treated over 10 years.
However, as early mentioned, the downside was that as-
pirin increased major gastrointestinal and extracranial
bleeding [6]. Since bleeding risk appeared to be strongly
related to the ischemic risk, the benefit of aspirin was
judged to be overshadowed by the bleeding hazard.
More recent meta-analyses suggested beneficial effects
for aspirin in the primary prevention of cardiovascular
events [8, 9, 30, 31, 59, 60]. Indeed, Bartolucci et al. [59]
reported in their meta-analysis that aspirin signifi-
cantly decreased the risk of total cardiovascular events
(OR 0.87, 95 % CI: 0.80–0.93; p <0.001) and nonfatal
MI (OR 0.81, 95 % CI: 0.67–0.99; p = 0.042), compared
with no aspirin, but there was a non-significant trend
for decreased risk of stroke, cardiovascular mortality,
and all-cause mortality. In the meta-analysis per-
formed by Raju et al. [60], primary prevention with
aspirin was associated with a reduction in all-cause
mortality (RR 0.94, 95 % CI: 0.88–1.00), MI (compos-
ite of fatal and nonfatal; RR, 0.83, 95 % CI: 0.69–1.00),
ischemic stroke (RR 0.86 95 % CI: 0.75–0.98), and the
composite of MI, stroke, and cardiovascular death (RR 0.88,
95 % CI: 0.83–0.94) in comparison with nonuse of aspirin.
In another meta-analysis conducted by Seshasai et al. [9],
aspirin association with a significant reduction in the risk of
cardiovascular events (OR, 0.90, 95 % CI: 0.85–0.96), was
primarily accounted for by a large reduction in the risk of
nonfatal MI (OR 0.80, 95 % CI: 0.67–0.96). No effect on
fatal MI was observed, but a modest non-significant reduc-
tion was apparent for all-cause mortality [9].
Moreover, the Multi-Ethnic Study of Atherosclerosis
that involved 4229 participants who were not on aspirin
at baseline and were free of diabetes mellitus revealed
that participants with significant plaque in their arteries
(i.e., CAC score ≥100) were estimated to be 2 to 4 times
more prone to prevent a heart attack with aspirin use
than to have a major bleed secondary to aspirin [27]. On
the contrary, participants with no calcified plaque (CAC
score = 0) were estimated to be 2 to 4 times more likely
to suffer a major bleed from aspirin use than to prevent
a heart attack with aspirin [27]. In the just-published
JPPP that included 14,464 patients aged 60–85 years and
presenting with either hypertension, dyslipidemia, or dia-
betes mellitus, low-dose aspirin (100 mg/day) significantly
reduced incidence of nonfatal MI (0.30, 95 % CI: 0.19-0.47
for aspirin vs. 0.58, 95 % CI: 0.42–0.81 for no aspirin; HR
0.53, 95 % CI: 0.31–0.91; p = 0.02) [24]. Likewise, it was
noticed a significant reduction in the incidence of transi-
ent ischemic attack (0.26, 95 % CI: 0.16–0.42 for aspirin
vs. 0.49, 95 % CI: 0.35–0.69 for no aspirin; HR 0.57, 95 %
CI: 0.32–0.99; p = 0.04) [24].
However, this study was terminated early, based on
likely futility. In fact, it appeared on the whole that aspirin
was unlikely to show a clinically important benefit in the
overall population included in the study [24]. The drug
did not significantly reduce the risk of the composite out-
come of cardiovascular death, nonfatal stroke, and nonfa-
tal MI, and the risk of bleeding significantly increased
Nansseu and Noubiap Thrombosis Journal  (2015) 13:38 Page 4 of 10
with aspirin [24]. In accordance with these findings, a
systematic review conducted by Jones et al. [61] showed
no differences between aspirin and placebo groups for
total and vascular mortality, MI, and stroke in patients
with asymptomatic peripheral artery disease. In the
same line, Brighton et al. [62] showed no reduction in
recurrent thromboembolic events with aspirin use of
100 mg/day even though there was a clear reduction in
the occurrence of other serious cardiovascular events
by 34 % (p = 0.01) compared to the placebo group. In
addition, no differences in bleeding or other serious
adverse events were observed [62]. The Aspirin for Asymp-
tomatic Atherosclerosis trial did not show a significant
reduction in fatal or non-fatal coronary event, stroke or re-
vascularization among participants without clinical CVD
identified with a low ABI and receiving aspirin in compari-
son with placebo [28].
Overall, in large-scale trials of primary prevention in
men and women without established CVD, and subse-
quent meta-analyses, aspirin significantly reduced the
risk of a first MI, but this was less the case for stroke
or cardiovascular death. But despite the apparent bene-
fits of aspirin therapy for primary prevention of CVD,
these benefits may be outweighed by the risk of major
bleeding (see Table 1) [6, 8, 9, 30, 31]. Indeed, a recent ex-
tensive systematic review of aspirin in primary prevention
Table 1 Summarizing published evidence for or against a beneficial effect of aspirin in primary prevention of cardiovascular disease




- A 12 % proportional reduction in serious
vascular events, mainly due to a reduction in
first nonfatal myocardial infarction
- No effect on stroke occurrence
- Increase in the risk of major gastrointestinal and other
extracranial bleeding by about 50 %
- Small protective effect on mortality - Increased incidence of hemorrhagic stroke (22 %)
Seshasai et al. [9] - Significant decrease in the risk of cardiovascular events
(notably nonfatal myocardial infarction)
No effect on fatal myocardial infarction
- Modest non-significant reduction in all-cause mortality
He et al. [21] Absolute risk reduction in myocardial infarction and
ischemic stroke
Increased risk of hemorrhagic stroke
De Beradis et al. [23] High incidence of major bleeding events with an overall





- Significant reduction in the incidence of nonfatal
myocardial infarction
- No significant diminution in the risk of the composite
outcome of cardiovascular death, nonfatal stroke, and
nonfatal myocardial infarction
- Significant reduction in the incidence of transient
ischemic attack - Increase in the risk of extracranial hemorrhage requiring
transfusion or hospitalization
The Multi-Ethnic Study of
Atherosclerosis [27]
Estimated 2–4 fold increased likelihood to prevent a heart
attack with aspirin use than to have a major bleed
secondary to aspirin in participants with significant plaque
in their arteries (i.e., CAC score ≥100).
Estimated 2–4 times increased probability to suffer a
major bleed from aspirin use than to prevent a heart
attack with aspirin in participants with no calcified




No significant reduction in fatal or non-fatal coronary event,
stroke or revascularization among participants without clinical
cardiovascular disease identified with a low ankle brachial
index and receiving aspirin in comparison with placebo
Bartolucci et al. [54] Significant decrease in the risk of total cardiovascular
events and nonfatal myocardial infarction
No effect on the reduction in the risk of stroke,
cardiovascular mortality, and all-cause mortality
Raju et al. [55] Reduction in all-cause mortality, myocardial infarction
(composite of fatal and nonfatal), ischemic stroke,
and the composite of myocardial infarction, stroke,
and cardiovascular death
Increase in the risk of hemorrhagic stroke, major bleeding,
and gastrointestinal bleeding
Jones et al. [56] No differences between aspirin and placebo groups for
total and vascular mortality, myocardial infarction, and
stroke in patients with asymptomatic peripheral artery
disease
Brighton et al. [57] - Reduction in the occurrence of serious cardiovascular
events (by 34 %) other than thromboembolic events
No reduction in recurrent thromboembolic events
(with aspirin use of 100 mg/day)
- No differences in bleeding or other serious adverse
events
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concluded that “there is a fine balance between benefits
and risks from regular aspirin use in primary prevention
of cardiovascular disease” [31].
The specific case of diabetes patients
Individuals with diabetes have a 2 to 4 fold increased
risk of developing cardiovascular events than those of
the same age and sex without diabetes [63]. Haffner et
al. [63] have shown that the risk of future CHD events is
similar for both diabetes subjects without prior CHD
and non-diabetes subjects with previous CHD. Besides, a
meta-analysis by the ATTC suggested that diabetes, in
addition to being an independent CVD risk factor, also
increased the risk of extracranial hemorrhage or bleed-
ing [6]. Conversely, Feigin et al. [64] reported a protect-
ive effect of diabetes on the incidence of subarachnoid
hemorrhages, which they justified by figuring out the
high risk of death from other causes in the population
with diabetes and therefore the chance of developing
such hemorrhages was smaller than in individuals with-
out diabetes.
The Early Treatment Diabetic Retinopathy Study
(ETDRS) [65] is the main study supporting the use of
aspirin in primary prevention of diabetes patients. This
multicenter, randomized clinical trial of aspirin versus
placebo investigated the effects of aspirin (325 mg/day)
in primary prevention on 3711 type 1 and type 2 dia-
betes patients aged 18–70 years old with various degrees
of retinopathy, and showed that aspirin did not affect
retinopathy progression, but was rather associated with
a reduction in the incidence of fatal and nonfatal MI
[65]. Consistent with these findings, the Physicians’
Health Study [66], a randomized double-blind placebo-
controlled trial designed to determine whether aspirin
decreased cardiovascular events in primary prevention
in patients with diabetes, demonstrated a significant re-
duction in the risk of MI, though without conclusive evi-
dence concerning stroke and total cardiovascular deaths.
Paradoxically, Simpson et al. [41] carried-out a meta-
analysis to examine the effect of dose on the association
between aspirin and cardiovascular outcomes using
data from 21 studies with 17,522 diabetes patients, and
found that aspirin use was not associated with a statis-
tically significant difference in mortality risk. More re-
cently, Sasso et al. [25] did not show a significant
difference in the incidence of both fatal (p = 0.225) and
nonfatal CV events (p = 0.573) between type 2 diabetes
patients with nephropathy placed on aspirin vs. pla-
cebo. These findings are in keeping with other studies
including the Japanese Primary Prevention of Athero-
sclerosis with Aspirin for Diabetes (JPAD) [29], the
Prevention and Progression of Arterial Disease and Dia-
betes (POPADAD) trial [67], the Primary Prevention Pro-
ject Trial [68] and the meta-analysis of seven randomized
clinical trials regrouping 11,000 patients and undertaken
by Butalia et al. [69]. On the whole, although aspirin may
not necessarily increase the risk of bleeding in diabetes pa-
tients, recent available data suggest no benefit in terms of
a reduction in vascular events.
Prescribe aspirin in primary prevention of CVD: a
challenging decision
Currently, the worthwhile net clinical benefit of giving as-
pirin to healthy individuals is made difficult to assess by
the imprecision of estimates of benefits and risks, espe-
cially for rare events, such as intracranial hemorrhage, and
by the difficulty of weighing ischemic versus bleeding
events [70, 71]. In the setting of secondary cardiovascular
prevention on the contrary, the benefit of treatment (sav-
ing major cardiovascular events) is clearly superior to the
risk (inducing major bleeding) [6].
The American Heart Association (AHA), the American
College of Chest Physicians (ACAP), and the European
Society of Cardiology (ESC) have formulated recommen-
dations for the use of low-dose aspirin for primary cardio-
vascular prevention with some of them being conflicting
(see Table 2). For instance, while the ACAP guidelines
suggests daily low-dose aspirin for persons age 50 years or
older without symptomatic CVD, ESC guidelines argues
that aspirin is “not recommeded in individuals without
cardiovascular or cerebrovascular disease” because of the
increased risk of major bleeding. Despite certain inconsis-
tences, all guidelines are clear that aspirin is inappropriate
for patients with aspirin intolerance and those at increased
risk of gastrointestinal bleeding or hemorrhagic stroke,
which is usually evident from a previous history of such
conditions. These aspirin contraindications are relatively
uncommon, however and happily, and the benefits of
CVD risk reduction typically outweigh the bleeding risks
for most patients at high CVD risk. It is worth noting that
aspirin doses of 75–162 mg per day are typically better
tolerated and are as effective as higher doses in conferring
cardiovascular protection [72].
Definitely, in primary CVD prevention, where the risk
of developing atherothrombotic events for each individual
patient is generally low, it is essential to estimate the indi-
vidual baseline risk of such events and to carefully balance
this against the side effects of therapy, in this case bleed-
ing. The ability to prevent serious cardiovascular events
and their associated sequelae with a single, inexpensive pill
makes low-dose aspirin therapy a worth considering low
cost option, specifically in impoverished areas. Therefore,
tailoring aspirin therapy according to baseline risk has
been proposed as the best practical guidance [11, 34, 70,
73]. As such, a threshold risk level should be defined,
above which recommending aspirin is expected to pro-
duce more benefit than risk, and assessed through the
most accurate and country-specific risk factor estimates.
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In this regard, the ESC working group on thrombosis has
proposed a threshold at a risk of major cardiovascular
events (death, MI and stroke) ≥ 2 per 100 patient-years
[70].
Any decision to prescribe aspirin should be an “indi-
vidual clinical judgment” that weighs the absolute bene-
fit in reducing the risk of a first cardiovascular event
against the absolute risk of major bleeding [73]. The
higher the absolute risk of CVD, the greater the net
benefit from aspirin. This final decision to initiate con-
tinuous aspirin therapy for primary prevention of CVD
should be made by health care providers [73], especially
Primary Care Physicians (PCPs) in resource-poor areas,
and they must therefore be cognizant of their role in
assessing the potential for benefit and subsequent risk of
bleeding in individual patients prior to starting the
treatment.
But mirroring previous findings, Fiscella et al. [74] fig-
ured out that the use of aspirin in primary prevention of
CVD is hindered by the clinician uncertainty in deter-
mining relative benefits and harms to patients. In fact,
they found that aspirin was recommended for only 34
and 42 % of eligible men and women, likely reflecting
the complexity of assessing patient eligibility, including
weighing benefits and harms in the context of risk calcu-
lations and age-based risk cutoffs [74]. In the absence of
hand-based or online risk calculators, physicians often
misjudge CVD global risk. It has therefore been sug-
gested that incorporation of automated CVD risk assess-
ments into electronic health records could improve
clinicians’ estimation of risk and recommendation for
prescribing [75]. But the implementation of such a
measure in resource-limited zones is questionable, given
that in most of these areas patients health records are
not yet computerized and local risk assessment tools are
lacking [14, 58]. In this regard, simple adapted tools
must be developed and PCPs be continuously trained to
use them.
Besides, engaging non-clinicians through expanded
care teams and standing orders may also prove helpful
in reducing the volume of decisions that rest solely with
the clinician at the point of care [74]. Indeed, sharing
care with team members can enhance the concordance
between published guidelines, use of risk models and ac-
tual practice [76]. Additionally, the relevant information
should be transferred to patients and, individual values
and preferences be taken into account. Indeed, patient
preferences may play a larger role, but consideration
must also be given to clinical equivalence as many pa-
tients may be more willing to experience a bleeding
event as opposed to suffering a heart attack [27]. It has
been stated that providing patients with global CVD risk
assessments seems to improve patient intent to initiate
CVD prevention [77].
Lastly, therapeutic lifestyle changes should be empha-
sized or reinforced [73]. In this line, populations should
be sensitized on healthy and life-saving attitudes (healthy
diets, physical activity, and smoking cessation among
others). Further, other life-saving drugs such as statins
could be considered with aspirin as an adjunct, or gastro-
intestinal protection be given in association with aspirin.
But these measures have shown controversial results and
Table 2 Recommendations for low-dose aspirin therapy in cardiovascular disease primary prevention
Organization Statement
American Heart Association/American
Stroke Association [78, 79]
a) The use of aspirin for cardiovascular (including but not specific to stroke) prophylaxis is reasonable
for people whose risk is sufficiently high (10-year risk >10 %) for the benefits to outweigh the risks
associated with treatment.
b) Aspirin can be useful for the prevention of a first stroke among women, including those with diabetes
mellitus, whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment.
c) Aspirin might be considered for the prevention of a first stroke in people with chronic kidney
disease (ie, estimated glomerular filtration rate <45 mL/min/1.73 m2). This recommendation does not
apply to severe kidney disease (stage 4 or 5; estimated glomerular filtration rate <30 mL/min/1.73 m2).
d) Aspirin is not useful for preventing a first stroke in low-risk individuals with or without diabetes.
e) Use of aspirin for primary cardiovascular prevention is reasonable in diabetic patients whose 10-year
risk of events is > 10 % (men age > 50 years and women age > 60 years with at least 1 additional risk
factor: smoking, hypertension, dyslipidemia, albuminuria, or family history of premature cardiovascular
events) and who are not at increased risk of bleeding (no history of gastrointestinal bleeding or peptic
ulcer disease, no concurrent use of other medications that increase bleeding risk).
f) Aspirin may be considered for diabetes patients at intermediate risk of cardiovascular events
(younger patients with at least 1 risk factor, older patients with no risk factors, or patients with a
10-year risk of 5 to 10 %)
American College of Chest Physicians
[32, 80]
Aspirin is recommended for the primary prevention of cardiovascular events in all patients aged
50 years or older with or without symptomatic cardiovascular disease.
Canadian Cardiovascular Society [81] Aspirin is not recommended in men or women without evidence of manifest vascular disease.
European Society of Cardiology [82] Aspirin is not recommended in individuals without cardiovascular or cerebrovascular disease.
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their implementation in resource-constraints settings
must be guided by cost-effective evidence.
Conclusion
The widespread and “appropriate” use of aspirin in pre-
vention of CVD is particularly attractive because the drug
is generally widely available and, more importantly for
developing countries where CVD is becoming the leading
cause of death, is extremely inexpensive. Although the
benefit of aspirin treatment is clear in secondary CVD
prevention, the evidence in primary prevention remains
unclarified. In fact, the studies revisited point out an in-
creased risk of major gastrointestinal, extracranial and
intracranial bleeding with continuous aspirin therapy.
Given this uncertainty about aspirin’s effects and the
differences in how people may assess the beneficial and
adverse consequences of aspirin use in primary CVD
prevention, providers and patients should routinely dis-
cuss aspirin use within the context of an overall strat-
egy for CVD prevention that is tailored to the patient’s
CVD risk. This risk must be calculated, based on accur-
ate and cost-benefit locally developed risk assessment
tools, and adequate thresholds be defined.
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